RYTM - Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals (NASDAQ: RYTM ) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. The full earnings call is available at Summary Rhythm Pharmaceuticals reported a strong second quarter 2026, with global net product sales of IMCIVREE totaling $71.3 million, marking a 19% sequential growth. The company launched IMCIVREE for acquired hypothalamic obesity (HO) in the U.S., receiving over 400 start forms from approximately 300 prescribers in the first 14 weeks post-FDA approval. Encouraging preliminary data from the Phase 2 trial of RM718 showed potential for clinically meaningful BMI reductions in patients with acquired HO, with a favorable tolerability profile. Rhythm Pharmaceuticals anticipates IMCIVREE approval and launch in Japan by the end of 2026, with plans to begin pricing discussions post-approval. The company updated its annual operating expense guidance to $363-$397 million for 2026, reflecting a shift in R&D expenses related to RM718 and bivamelagon from late 2026 to early 2027. Full Transcript OPERATOR Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals second quarter 2026 earnings conference call. At this time all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Dave Connolly, Investor Relations at Rhythm Pharmaceuticals. Please go ahead. Dave Connolly, Investor Relations Thank you, Dede. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the investors section of our website, ir.rhythmtx.com. This morning we issued our press release that provides our Q2 2026 financial results and a business update, and that press release is available on our website. We also released data for RM718's Phase 2 trial in acquired hypothalamic obesity. Our agenda today is listed on slide 2. On the call are David Meeker, our Chairman, Chief Executive Officer and President; Jennifer Lee, Executive Vice President, Head of North America; Hunter Smith, Chief Financial Officer; and Jan Massabro, Executive Vice President, Head of International, is on the line joining us from Europe. On slide 3, I'll remind you this call contains remarks concerning future expectations, plans and prospects, which constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various impor